Trial intelligence / Profile preview

Linagliptin Add-on to Metformin in Type 2 Diabetes

NCT00601250Phase 3Completed

Sponsor
Boehringer Ingelheim
Start
Jan 2008
Primary completion
May 2009
Modality
Small Molecules
Countries
10
01

Overview

A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Jan 2008; status: completed.

02

Drugs

linagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT00601250.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00601250.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call